Xcout Intel
DeVoro Medical Inc.
Devoro Medical, Inc. is a medical device company developing a mechanical thrombectomy platform for peripheral interventions. The company has received strategic investment from Marlborough, Massachusetts-based Boston Scientific, which announced an agreement to acquire Devoro Medical.
Subscribe to see DeVoro Medical Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
DeVoro Medical Inc. at a glance
DeVoro Medical Inc. is a medical devices & publishing company headquartered in United States. It has raised at least $32M across the 3 funding rounds on record. Its most recent funding round, Series A, raised $5.5M in December 2021. Xcout tracks 1 named person at DeVoro Medical Inc., including Mary Ann Cooke (Vice President, Life Sciences).
DeVoro Medical Inc. leadership
- Mary Ann CookeVice President, Life Sciences
DeVoro Medical Inc. funding rounds
At least $32M raised across the 3 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $5.5M | 1 named | |
| SEC Form D filing | $18M | — | |
| SEC Form D filing | $8.5M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
DeVoro Medical Inc. competitors
A few of DeVoro Medical Inc.'s closest competitors — see the full list of competitors and alternatives →
Boston Scientific Corporation operates as a global medical technology firm, specializing in the design, production, and worldwide distribution of innovative medical devices tailored for various interventional specialties. The company's operations are strategically divided into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Through its MedSurg division, Boston Scientific provides critical diagnostic and therapeutic tools aimed at addressing conditions affecting the gastrointestinal and pulmonary systems, alongside a diverse portfolio of solutions for urological and pelvic health issues. The Rhythm and Neuro segment is dedicated to advanced cardiac rhythm management and neurological interventions. Its product offerings encompass implantable cardioverter-defibrillators (ICDs), cardiac resynchronization therapy (CRT) defibrillators, and pacemakers (including CRT pacemakers), all complemented by remote patient monitoring platforms. This segment also delivers sophisticated technologies for assessing and treating cardiac rate and rhythm irregularities, featuring solutions such as 3-D mapping and navigation systems, various ablation and diagnostic catheters, intracardiac ultrasound catheters, and related accessories. In the neurological domain, it furnishes spinal cord stimulator systems for managing chronic pain, indirect decompression systems, and deep brain stimulation systems. Boston Scientific's Cardiovascular segment presents an extensive array of products focused on heart and vascular health. This includes cutting-edge interventional cardiology solutions like drug-eluting coronary stent systems for treating coronary artery disease, as well as percutaneous coronary intervention (PCI) instruments designed to tackle atherosclerosis. The segment further provides intravascular catheter-directed ultrasound imaging and fractional flow reserve (FFR) devices, applicable in coronary arteries, heart chambers, and peripheral vessels, in addition to structural heart therapies. Beyond this, the company supplies stents, balloon catheters, wires, and atherectomy systems for arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents for venous conditions; and a comprehensive suite of products for cancer treatment, including peripheral embolization devices, radioactive microspheres, various ablation systems (such as cryotherapy), and micro/drainage catheters. Established in 1979, the corporation maintains its headquarters in Marlborough, Massachusetts.
FARAPULSE, Inc. is a medical technology company specializing in biotechnology and cardiovascular solutions, headquartered in Menlo Park, California, and subsequently acquired by Boston Scientific.
AtheroMed, Inc. was a U.S. medical-device company that developed catheter-based atherectomy technology, including the Phoenix Atherectomy System, for removing plaque from peripheral arteries. Its products were intended for vascular and interventional physicians treating patients with peripheral arterial disease.
Xlumena, Inc. was a venture-backed medical device company that developed, manufactured, and sold minimally invasive, image-guided therapeutic endoscopy products for gastrointestinal procedures. In 2015, the San Diego-based company was acquired by Boston Scientific.
Get DeVoro Medical Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on DeVoro Medical Inc. in Xcout Intel
- 1 named person with titles, LinkedIn and board committees
- 3 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access